| Literature DB >> 26051475 |
Hanyu Zeng1, Rong Zhang1, Boquan Jin1, Lihua Chen1.
Abstract
The lack of immune response to an antigen, a process known as immune tolerance, is essential for the preservation of immune homeostasis. To date, two mechanisms that drive immune tolerance have been described extensively: central tolerance and peripheral tolerance. Under the new nomenclature, thymus-derived regulatory T (tT(reg)) cells are the major mediators of central immune tolerance, whereas peripherally derived regulatory T (pT(reg)) cells function to regulate peripheral immune tolerance. A third type of T(reg) cells, termed iT(reg), represents only the in vitro-induced T(reg) cells(1). Depending on whether the cells stably express Foxp3, pT(reg), and iT(reg) cells may be divided into two subsets: the classical CD4(+)Foxp3(+) T(reg) cells and the CD4(+)Foxp3(-) type 1 regulatory T (Tr1) cells(2). This review focuses on the discovery, associated biomarkers, regulatory functions, methods of induction, association with disease, and clinical trials of Tr1 cells.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26051475 PMCID: PMC4579656 DOI: 10.1038/cmi.2015.44
Source DB: PubMed Journal: Cell Mol Immunol ISSN: 1672-7681 Impact factor: 11.530